Servier

70% of new precision medicines approved by FDA in past three years were not sponsored by major pharmas

Michael Kingston and Dale Raine on the capital markets and global deal-making landscape

Agency approved seven new therapies in August, plus four new product formulations or dosages

After starting the month with two approvals, FDA’s remaining decisions include Gilead’s seladelpar, Regeneron’s BCMAxCD3 bispecific 

Plus: Rampart raises $85M series A for DNA-based therapies and updates from Servier, Novartis, Cargo and more

Plus: Josh Schimmer, Eric Schmidt join Cantor 

CHMP’s June opinions: Amylyx therapy denied, plus positive opinions for two new medicines and eight label extensions

Standout data from Servier, Day One in glioma at ASCO

Plus: Siren, Sania debut and updates from Aitia, PTC, enGene, Ardelyx, Akero and Satellos   

Plus: Servier’s vorasidenib meets glioma endpoint and updates from Teitur, AlgoTx, GSK, Acesion, Sophia Genetics and more